Back | Next |
home / stock / apre / apre message board
Subject | By | Source | When |
---|---|---|---|
CASH ON HAND $77 MILLION | Jimmy Quick | investorshub | 06/23/2021 2:23:41 PM |
Overview We are a clinical-stage biopharmaceutical company focused on | Jimmy Quick | investorshub | 06/21/2021 7:54:37 PM |
I know this isn't a NASDAQ message board. | Jimmy Quick | investorshub | 06/18/2021 5:15:08 PM |
Totally agree, I have been loading up at | Jimmy Quick | investorshub | 06/17/2021 7:18:32 PM |
Pump and dump pos imo?? | Roadtojourney | investorshub | 06/16/2021 5:31:20 PM |
sold some $APRE on the pop today. | NATURES WAY | investorshub | 06/11/2021 4:24:51 PM |
loaded shares of apre today. Seems to be | NATURES WAY | investorshub | 05/07/2021 2:21:38 AM |
Got my order in at $20+. | Natureboy1 | investorshub | 04/08/2021 1:12:22 PM |
$APRE is extemely undervalued chart shows the significant | lukin4winners | investorshub | 02/11/2021 2:54:31 PM |
ready to fill that huge gap. | aristotelisonassis | investorshub | 02/10/2021 8:44:13 PM |
I agree. This stock is demanding attention and | RockStarInvestor | investorshub | 01/23/2021 2:47:47 PM |
I'm in @ 5.69 looks good from here | toytundra | investorshub | 01/22/2021 5:33:00 PM |
$APRE Chart and indicators looks ready for a | aristotelisonassis | investorshub | 01/21/2021 12:56:43 PM |
Jan 28th marks the end of the waiting | RockStarInvestor | investorshub | 01/19/2021 5:22:35 PM |
Jan 28th marks the end of the waiting | RockStarInvestor | investorshub | 01/19/2021 5:21:40 PM |
Another buying opportunity has appeared. Looking forward to | RockStarInvestor | investorshub | 01/15/2021 6:22:52 PM |
Welcome! There is alot of information on the | RockStarInvestor | investorshub | 01/15/2021 6:14:19 PM |
Hello just found this company on another bio | Harbor6460 | investorshub | 01/15/2021 2:14:23 AM |
After a great premarket open the profit takers | RockStarInvestor | investorshub | 01/13/2021 6:03:44 PM |
It's good to know they are still a | RockStarInvestor | investorshub | 01/13/2021 2:29:20 PM |
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NASDAQ Market:
Aprea Therapeutics Inc. Website:
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...